.Competing enthusiasms.J.L.M. reports institutional research study backing coming from AstraZeneca, Seagen, Sermonix and also Olema as well as consultatory and also getting in touch with tasks along with Pfizer, Seagen, Sermonix, Novartis, Stemline, AstraZeneca, Olema, GlaxoSmithKline and also GE Healthcare. C.Y.
states institutional research grant from NCI/NIH compensation assistance and also travel repayment coming from QLHC a United States license entitled u00e2 $ Bosom cancer action forecast subtypesu00e2 $ (no. 18/174,491) and also University of California Inventor Allotment. H.S.R.
mentions institutional analysis assistance from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmannu00e2 $ “La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly Merck and also Co., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Rehabs, OBI Pharma, Ambrx, Greenwich Pharma as well as advising and also consulting functions along with Chugai, The Puma Corporation, Sanofi, Napo and also Mylan. R.N.
records investigation backing coming from Arvinas, AstraZeneca, BMS, Corcept Therapies, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sunlight Pharma and also Taiho as well as advisory tasks along with AstraZeneca, BeyondSpring, Daiichi Sankyo, Particular Sciences, Fujifilm, GE, Gilead, Guardant Health, Infinity, iTeos, Merck, Moderna, Novartis, OBI, OncoSec, Pfizer, Sanofi, Seagen and also Stemline. M.D. discloses research grants from NIH/NCI as well as NIH/NIA, and arrangements coming from PCORI.
A.J.C. reports institutional investigation funding coming from Merck, Amgen, Puma, Seagen, Pfizer as well as Olema and advising duties with AstraZeneca and also Genentech. A.Z.
discloses institutional research study funding from Merck, honoraria for Medscape and also engagement on Pfizer Advisory Board. A.S.C. reports institutional investigation financing from Novartis and Lilly.
A.D.E. reports support from Scorpion, Infinity and also Deciphera. E.S.-R.
records grants from V Groundwork, NIH, Susan G. Komen institutional analysis financing from GSK, Seagen, Pfizer, Lilly consulting as well as gratuity coming from Novartis, Merck, Seagen, AstraZeneca, Lilly Cancer Cells Recognition System Panel member and support from ASCO as well as NCCN. J.C.B.
discloses institutional analysis funding from Eli Lilly and also Synergy, participation on the Data Safety Observing Committee of Surgical and also gratuity from PER, PeerView, OncLive, EndoMag and also UpToDate. C.V. mentions institutional research study backing from Pfizer, Seagen, H3 Biomedicine/Eisai, AstraZeneca, CytomX research study financing to previous company coming from Genentech, Roche, Pfizer, Incyte, Pharmacyclics, Novartis, TRACON Pharmaceuticals, Innocrin Pharmaceuticals, Zymeworks and also H3 Biomedicine advisory and also speaking to functions along with Guidepoint, Novartis, Seagen, Daiichi Sankyo, AstraZeneca and also Cardinal Wellness overdue consulting with Genentech and participation in non-CME activity along with Gilead, AstraZeneca.
C.O. states consulting fees from AstraZeneca, Guardant Wellness and also Jazz Drugs. K.S.A.
mentions institutional analysis funding from AstraZeneca, Daiichi Sankyo, Seat Genes as well as QLHC Independent Information and also Protection Observing board at Seat Genetics. K.M.K. states advisory and expert tasks for Eli Lilly, Pfizer, Novartis, AstraZeneca, Daiichi Sankyo, The Puma Corporation, 4D Pharma, OncoSec, Immunomedics, Merck, Seagen, Mersana, Menarini Silicon Biosystems, Myovant, Takeda, Biotheranostics, Regor, Gilead, Start Therapies, RayzeBio, eFFECTOR Therapeutics and Cullinan Oncology as well as files institutional study financing coming from Genentech/Roche, Novartis, Eli Lilly, AstraZeneca, Daiichi Sankyo and also Ascentage.
C.I. mentions institutional research backing from Tesaro/GSK, Seattle Genes, Pfizer, AstraZeneca, BMS, Genentech, Novartis as well as Regeneron consultancy tasks with AstraZeneca, Genentech, Gilead, ION, Merck, Medscape, MJH Holdings, Novartis, Pfizer, Puma and also Seagen and royalties from Wolters Kluwer (UptoDate) and also McGraw Hill (Goodman and also Gillman). J.T.
acts as institutional main investigator for scientific test with User-friendly Surgical editor top for abdominal muscle, CGSO, SCORE, Boob Learning Committee Monitor Forerunner, ASCO SESAP 19 and Breast Co-Chair, ACS. A.T. possesses sell at Johnson and also Johnsons, Gilead, Bristol Myers Squibb, states involvement on Pfizer Advisory Board: AstraZeneca and also records institutional analysis backing coming from Merck as well as Sanofi as well as royalties from UptoDate.
R.B. states a consultancy task at Genentech as well as inventory ownership at Cerus Corp. K.Y.
received research study help unassociated to this work as well as spent to the company coming from Pfizer, Gilead, Seagen, Dantari Pharmaceuticals, Treadwell Therapies, and Relay Therapies help coming from American Cancer cells Community IRG grant no. IRG-19-230-48-IRG, UC San Diego Moores Cancer Cells Center, Specialized Cancer cells Facility support grant NIH/NCI P30CA023100, Curebound Discovery Award (2023, 2024). T.S.
reports gratuity from Hologic. L.P. reports institutional analysis financing coming from Susan Komen Foundation, Boob Cancer Research Study Base, NCI, Pfizer, AstraZeneca, Menarini/Stemline, Bristol Myers Squibb, Merck as well as Co.
consulting fees from AstraZeneca, Merck, Novartis, Genentech, Natera, Personalis, Precise Sciences and Stemline/Menarini license labelled u00e2 $ Technique of gauging residual cancer and also predicting individual survivalu00e2 $ (no. 7711494) and also Records and also Safety Tracking Board member of the DYNASTY Breast02, OPTIMA and also PARTNER trials. M.S.T.
states institutional analysis funding from Lilly, Gilead Sciences, Phoenix Az Molecular Designs, AstraZeneca, Regeneron, Merck and Novartis. A.L.A., P.B. as well as P.N.
are actually workers of QLHC. G.L.H. states institutional analysis give coming from NIH (1R01CA255442).
W.F.S. states allotments of IONIS Pharmaceuticals as well as Eiger Biopharmaceuticals, got consulting charges from AstraZeneca, is a cofounder along with equity in Delphi Diagnostics and also issued licenses for (1) a method to calculate recurring cancer cells burden and (2) genomic trademark to assess sensitiveness to hormonal therapy. J.P.
states honoraria coming from Methods in Professional Researchu00e2 $” professors heir shop support coming from ASCO as well as advocate scholarship AACRu00e2 $” SSP plan VIVLI, U Wisc SPOREu00e2 $” EAB, QuantumLEADu00e2 $” COVID DSMB, PCORIu00e2 $” evaluator as well as I-SPY supporter lead. P.P. discloses institutional investigation financing coming from Genentech/Roche, Fabre-Kramer, Advanced Cancer Cells Therapeutics, Caris Centers of Excellence, Pfizer, Pieris Pharmaceuticals, Cascadian Therapy, Bolt, Byondis, Seagen, Orum Rehabs as well as Carisma Therapies consulting charges coming from Tailored Cancer cells Treatment, OncoPlex Diagnostics, Immunonet BioSciences, Pfizer, HERON, The Puma Corporation Biotechnology, Sirtex, CARIS Life sciences, Juniper, Bolt Biotherapeutics as well as AbbVie gratuity coming from DAVA Oncology, OncLive/MJH Lifestyle Sciences, Frontiersu00e2 $” author, SABCS and ASCO Speakersu00e2 $ Bureau: Genentech/Roche (previous) United States license no.
8486413, USA license no. 8501417, United States license no. 9023362, USA license no.
9745377 unremunerated functions along with Pfizer, Seagen and Jazz. R.A.S. states institutional study funding coming from OBI Pharma, QLHC, AstraZeneca and also Gilead, provides on AstraZeneca as well as Stemline Advisory Boards and also Gilead Speakeru00e2 $ s Agency and also documents working as a consultant function with QLHC.
A.D. mentions institutional analysis backing from Novartis, Pfizer, Genentech and also NeoGenomics Plan Seat, Scientific Advisory Board, ASCO. D.Y.
mentions investigation backing coming from NIH/NCI P30 CA 077598, P01 CA234228-01 and R01CA251600, consulting with expenses from Martell Diagnostics, as well as gratuity and also trip for communicating at the u00e2 $ Global Boob Cancer Cells Conference.u00e2 $ L.J.v.V. is a founding consultant and shareholder of Exai Biography as well as is a part-time employee and possesses inventory in Agendia. N.M.H.
discloses institutional research funding coming from NIH. L.J.E. states financing from Merck as well as Co., engagement on a board of advisers for Blue Cross Blue Shield and also private costs from UpToDate and also is actually an unpaid board member of QLHC.
The various other authors proclaim no completing rate of interests.